News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,206 Results
Type
Article (43769)
Company Profile (318)
Press Release (697106)
Multimedia
Podcasts (117)
Webinars (19)
Section
Business (210976)
Career Advice (2107)
Deals (36757)
Drug Delivery (123)
Drug Development (83409)
Employer Resources (177)
FDA (16814)
Job Trends (15499)
News (357316)
Policy (34121)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2610)
Accelerated approval (31)
Adcomms (26)
Allergies (143)
Alliances (51584)
ALS (171)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (318)
Approvals (17074)
Artificial intelligence (523)
Autoimmune disease (146)
Automation (37)
Bankruptcy (372)
Best Places to Work (11771)
BIOSECURE Act (21)
Biosimilars (193)
Biotechnology (188)
Bladder cancer (157)
Brain cancer (59)
Breast cancer (641)
Cancer (4826)
Cardiovascular disease (410)
Career advice (1786)
Career pathing (36)
CAR-T (279)
CDC (47)
Celiac Disease (2)
Cell therapy (744)
Cervical cancer (36)
Clinical research (71078)
Collaboration (1723)
Company closure (4)
Compensation (1147)
Complete response letters (60)
COVID-19 (2782)
CRISPR (93)
C-suite (837)
Cystic fibrosis (148)
Data (6184)
Decentralized trials (2)
Denatured (36)
Depression (133)
Diabetes (501)
Diagnostics (6755)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (249)
Drug pricing (203)
Drug shortages (31)
Duchenne muscular dystrophy (227)
Earnings (91764)
Editorial (58)
Employer branding (22)
Employer resources (155)
Events (120114)
Executive appointments (984)
FDA (19924)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1462)
Gene editing (199)
Generative AI (44)
Gene therapy (605)
GLP-1 (1010)
Government (4795)
Grass and pollen (7)
Guidances (384)
Healthcare (19052)
HIV (55)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (256)
Immuno-oncology (54)
Indications (104)
Infectious disease (3041)
Inflammatory bowel disease (192)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (247)
Interviews (326)
IPO (16917)
IRA (56)
Job creations (4069)
Job search strategy (1498)
JPM (63)
Kidney cancer (15)
Labor market (83)
Layoffs (575)
Leadership (32)
Legal (8421)
Liver cancer (92)
Longevity (15)
Lung cancer (646)
Lymphoma (374)
Machine learning (43)
Management (60)
Manufacturing (805)
MASH (166)
Medical device (13839)
Medtech (13891)
Mergers & acquisitions (20899)
Metabolic disorders (1286)
Multiple sclerosis (155)
NASH (17)
Neurodegenerative disease (314)
Neuropsychiatric disorders (89)
Neuroscience (2915)
Neurotech (1)
NextGen: Class of 2026 (6646)
Non-profit (4557)
Now hiring (65)
Obesity (607)
Opinion (282)
Ovarian cancer (165)
Pain (213)
Pancreatic cancer (224)
Parkinson's disease (281)
Partnered (34)
Patents (494)
Patient recruitment (474)
Peanut (58)
People (60836)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22067)
Phase 2 (31251)
Phase 3 (23422)
Pipeline (5115)
Policy (295)
Postmarket research (2655)
Preclinical (9377)
Press Release (68)
Prostate cancer (236)
Psychedelics (49)
Radiopharmaceuticals (283)
Rare diseases (848)
Real estate (6304)
Recruiting (72)
Regulatory (25312)
Reports (51)
Research institute (2434)
Resumes & cover letters (360)
Rett syndrome (27)
RNA editing (17)
RSV (76)
Schizophrenia (154)
Series A (243)
Series B (187)
Service/supplier (11)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (160)
Sponsored (42)
Startups (3763)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (79)
Vaccines (1013)
Venture capital (88)
Weight loss (400)
Women's health (87)
Worklife (18)
Date
Today (22)
Last 7 days (600)
Last 30 days (2351)
Last 365 days (30278)
2026 (2852)
2025 (30682)
2024 (35769)
2023 (40630)
2022 (51799)
2021 (56330)
2020 (54793)
2019 (47398)
2018 (35771)
2017 (33138)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (802)
Alabama (83)
Alaska (7)
Arizona (312)
Arkansas (14)
Asia (42120)
Australia (6744)
California (11221)
Canada (3273)
China (1122)
Colorado (474)
Connecticut (471)
Delaware (336)
Europe (90244)
Florida (1667)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (868)
India (65)
Indiana (523)
Iowa (22)
Japan (429)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1379)
Massachusetts (8080)
Michigan (322)
Minnesota (625)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2985)
New Mexico (29)
New York (2961)
North Carolina (1457)
North Dakota (8)
Northern California (5458)
Ohio (331)
Oklahoma (22)
Oregon (46)
Pennsylvania (2271)
Puerto Rico (22)
Rhode Island (47)
South America (1176)
South Carolina (66)
South Dakota (1)
Southern California (4367)
Tennessee (172)
Texas (1733)
United States (39890)
Utah (336)
Vermont (1)
Virginia (272)
Washington D.C. (81)
Washington State (923)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
741,206 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
October 28, 2025
·
4 min read
·
Tristan Manalac
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Press Releases
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
January 13, 2026
·
4 min read
Press Releases
Veeva and BioMarin Form Long-Term Strategic Partnership
January 9, 2026
·
4 min read
Press Releases
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
January 27, 2026
·
5 min read
Press Releases
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
January 30, 2026
·
5 min read
Rare diseases
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
January 9, 2026
·
1 min read
Press Releases
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
December 22, 2025
·
23 min read
1 of 74,121
Next
